中晚期肝癌患者应用TACE联合PMCT治疗的效果分析

Analysis of the effect of TACE combined with PMCT in patients with advanced liver cancer

目的探究中晚期肝癌患者应用TACE联合PMCT治疗的效果。方法2018年3月—2020年4月宜兴市人民医院收治的中晚期肝癌患者60例,随机分为2组,每组30例,短间隔组患者TACE治疗同步PMCT治疗,长间隔组患者TACE治疗后1个月行PMCT治疗。于患者治疗3个月后比较临床疗效、甲胎蛋白、异常凝血酶原水平、2年生存率。结果短间隔组和长间隔组治疗后客观缓解率分别为43.33%、36.67%,2组治疗后客观缓解率比较差异均无统计学意义(P>0.05)。治疗后,短间隔组血清甲胎蛋白、异常凝血酶原水平分别为[(107.43±15.32)ng/mL、(2831.26±118.50)mAU/mL];长间隔组血清甲胎蛋白、异常凝血酶原水平分别为[(135.02±12.51)ng/mL、(3135.65±107.28)mAU/mL],2组治疗后血清甲胎蛋白、异常凝血酶原低于治疗前,短间隔组更低(P<0.05)。长间隔组和短间隔组2年总生存率分别为23.08%、46.43%,2组生存曲线比较差异有统计学意义(P<0.05)。结论TACE治疗同期行PMCT更有助于抑制中晚期肝癌患者的肿瘤因子表达,延长生存期,安全性良好。

Objective To explore the effect of combining TACE with PMCT in patients with advanced liver cancer.Methods From March 2018 to April 2020,60 patients with advanced liver cancer admitted to Yixing People′s Hospital were randomly divided into two groups,with 30 patients in each groups.The patients in the short interval group received simultaneous treatment with TACE and PMCT.The patients in the long interval group received PMCT one month after TACE.After 3 months of treatment,the clinical efficacy,AFP,abnormal prothrombin levels and 2-year survival rate were compared.Results The objective remission rates of short interval group and long interval group after treatment were 43.33%and 36.67%respectively,and there was no significant difference between the two groups(P>0.05).After treatment,the levels of serum AFP and abnormal prothrombin in the short interval group were(107.43±15.32)ng/mL and(2831.26±118.50)mAU/mL,respectively.In the long interval group,the levels of serum AFP and abnormal prothrombin were(135.02±12.51)ng/mL and(3135.65±107.28)mAU/mL,respectively.Both groups showed lower levels of serum AFP and abnormal prothrombin after treatment compared to before treatment,with the short interval group showing a greater reduction(P<0.05).The 2-year overall survival rates of the long interval group and the short interval group were 23.08%and 46.43%,respectively.The survival curves of the two groups were statistically different(P<0.05).Conclusion PMCT at the same time of TACE treatment is more helpful in inhibiting the expression of tumor factors in patients with advanced liver cancer,prolonging the survival period,and ensuring good safety.